HomeCompareSMED vs JNJ

SMED vs JNJ: Dividend Comparison 2026

SMED yields 22.86% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMED wins by $56.6K in total portfolio value
10 years
SMED
SMED
● Live price
22.86%
Share price
$8.75
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$86.9K
Annual income
$9,043.33
Full SMED calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SMED vs JNJ

📍 SMED pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMEDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMED + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMED pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMED
Annual income on $10K today (after 15% tax)
$1,942.86/yr
After 10yr DRIP, annual income (after tax)
$7,686.83/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SMED beats the other by $3,700.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMED + JNJ for your $10,000?

SMED: 50%JNJ: 50%
100% JNJ50/50100% SMED
Portfolio after 10yr
$58.6K
Annual income
$6,866.36/yr
Blended yield
11.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SMED
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMED buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMEDJNJ
Forward yield22.86%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$86.9K$30.3K
Annual income after 10y$9,043.33$4,689.40
Total dividends collected$52.8K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMED vs JNJ ($10,000, DRIP)

YearSMED PortfolioSMED Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,986$2,285.71$10,592$272.30+$2.4KSMED
2$16,669$2,773.98$11,289$357.73+$5.4KSMED
3$21,163$3,327.79$12,123$472.89+$9.0KSMED
4$26,593$3,948.70$13,141$629.86+$13.5KSMED
5$33,092$4,637.26$14,408$846.81+$18.7KSMED
6$40,802$5,392.98$16,021$1,151.60+$24.8KSMED
7$49,872$6,214.37$18,122$1,588.22+$31.8KSMED
8$60,462$7,098.94$20,930$2,228.20+$39.5KSMED
9$72,738$8,043.32$24,792$3,191.91+$47.9KSMED
10$86,873$9,043.33$30,274$4,689.40+$56.6KSMED

SMED vs JNJ: Complete Analysis 2026

SMEDStock

Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste generated outside the hospital and health care facility settings; TakeAway Recovery System to treat used needles, syringes, and other used healthcare products; Route-Based Pickup Service, a medical and hazardous waste pick-up services; and MedSafe, a solution for the safe collection, transportation, and disposal of unwanted and expired ultimate-user medications. The company also provides TakeAway Medication Recovery System that facilitates the proper disposal of unused medications; Black Pail Program for Rx, a solution with minimal segregation for the disposal of various pharmaceuticals; Inhaler Disposal to collect, transport, and destroy used pharmaceutical inhalers; Hazardous Drug Spill Control Kit for the cleanup of chemotherapy and other HD spills; TakeAway Recycle System for the collection and recycling of single-use medical devices from surgical centers and other healthcare facilities; ComplianceTRAC, a Web-based compliance and training program; and Universal Waste Shipback Systems to collect, transport, and recycle light bulbs, batteries, and other mercury containing devices. In addition, it offers other solutions, such as TakeAway Environmental Return System, SharpsTracer, Sharps Secure, Needle Disposal System, Complete Needle Collection and Disposal System, Pitch-It IV Poles, Asset Return System, and Spill Kit Recovery System, as well as Sharps MWMS, a medical waste management system. The company serves customers in home health care, retail clinics and immunizing pharmacies, pharmaceutical manufacturers, professional offices, assisted living and long-term care facilities, and government agencies, as well as distributors. Sharps Compliance Corp. was founded in 1992 and is headquartered in Houston, Texas.

Full SMED Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SMED vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMED vs SCHDSMED vs JEPISMED vs OSMED vs KOSMED vs MAINSMED vs ABBVSMED vs MRKSMED vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.